Millie Capital Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,873 shares of the company’s stock after selling 1,000 shares during the period. Millie Capital Management LLC’s holdings in Johnson & Johnson were worth $907,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Johnson & Johnson during the third quarter worth $104,000. Hefty Wealth Partners raised its position in shares of Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock worth $132,000 after buying an additional 951 shares in the last quarter. Wechter Feldman Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $209,000. New Capital Management LP purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $214,000. Finally, Turner Investments LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $218,000. Institutional investors own 65.30% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 125.48 on Friday. The firm has a 50-day moving average price of $121.86 and a 200 day moving average price of $117.35. The firm has a market capitalization of $340.47 billion, a price-to-earnings ratio of 21.16 and a beta of 0.74. Johnson & Johnson has a one year low of $107.69 and a one year high of $129.00.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.02. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The business earned $18.10 billion during the quarter, compared to the consensus estimate of $18.28 billion. During the same period in the previous year, the business earned $1.44 EPS. The business’s quarterly revenue was up 1.7% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post $7.04 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend was Friday, February 24th. Johnson & Johnson’s payout ratio is currently 54.42%.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Web Breaking News and is owned by of Web Breaking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at http://www.webbreakingnews.com/2017/03/26/johnson-johnson-jnj-shares-sold-by-millie-capital-management-llc.html.
A number of brokerages have recently weighed in on JNJ. Jefferies Group LLC reissued a “hold” rating and issued a $107.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 20th. Royal Bank of Canada reissued a “buy” rating and issued a $133.00 price objective on shares of Johnson & Johnson in a report on Friday, January 6th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $117.64 price objective on the stock in a report on Tuesday, November 29th. Finally, Goldman Sachs Group Inc cut their price objective on Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating on the stock in a report on Wednesday, January 25th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $124.09.
In other news, VP Paulus Stoffels sold 22,000 shares of the business’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total value of $2,580,380.00. Following the completion of the sale, the vice president now directly owns 127,650 shares of the company’s stock, valued at approximately $14,972,068.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.11% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.